 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Biogen, Inc.
 |
Biogen, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
VW Mexico unit's striking workers to lower wage demand Aug 22 2001 10:47 AM PDT
Biogen, Serono both claim victory in MS court spat Aug 19 2001 03:14 AM PDT
Biogen says Geneva court upholds injunction vs Serono Aug 18 2001 06:47 AM PDT
Funds: Fund investors eye biotech Aug 16 2001 09:33 AM PDT
Funds: Fund investors eye biotech Aug 16 2001 09:33 AM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
Quiet, Please, Meeting About to Start
Jun 25 2001 10:07 AM PDT
Dow Takes the High Road, and the Nasdaq? Well...
Apr 11 2000 03:37 PM PDT
PROFILE |
 |
AVONEX calling? No peddler of cosmetics, Biogen develops biopharmaceuticals to treat a variety of ailments, primarily autoimmune conditions. Its flagship drug is AVONEX, a treatment for relapsing multiple sclerosis (MS) that accounts for about 80% of the firm's sales. Biogen licenses the drug to Schering-Plough, with which it is fighting over royalties. Facing a decline in revenues, the company is developing AMEVIVE, a potential treatment for psoriasis. Other drug candidates include a drug for MS and Crohn's disease. Biogen also makes money by licensing to other companies drugs it has developed; such products include alpha interferon and a hepatitis B vaccine, licensed to Merck, Abbott Laboratories, and others.
COMPETITION |
 |
Schering AG (SHR)
Serono S.A. (SRA)
Teva Pharmaceutical Industries Limited (TEVA)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 926.50
1-Yr. Sales Growth: 16.6%
Employees: 1,475
Revenue per employee: $628,135.59
KEY PEOPLE |
 |
James C. Mullen
CEO
Peter N. Kellogg
CFO
CONTACT INFO |
 |
14 Cambridge Center
Cambridge, MA 02142
US
Phone: 617-679-2000
Fax: 617-679-2617
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |